11 research outputs found
Global treatment standard in multiple myeloma remains elusive: Updated results from the INSIGHT MM global, prospective, observational study
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Results from a phase II study of isatuximab as a single agent and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma
Outcomes for patients with multiple myeloma (MM) have improved
significantly over the past decade. Despite these advances, MM remains
incurable and an unmet medical need remains for patients who are
relapsed and/or refractory. Panobinostat is a potent, oral
pan-deacetylase inhibitor that elicits anti-myeloma activity through
epigenetic modulation of gene expression and disruption of protein
metabolism. Preclinical data demonstrated that panobinostat has
synergistic effects on myeloma cells when combined with bortezomib and
dexamethasone. In a Phase III clinical trial evaluating bortezomib and
dexamethasone in combination with panobinostat or placebo in patients
with relapsed or relapsed and refractory MM (PANORAMA 1), panobinostat
led to a significant increase in median progression-free survival.
Panobinostat is currently under regulatory review with a recent
accelerated approval granted for the treatment of relapsed disease, in
which both bortezomib and immunomodulatory drugs have failed. Here, we
summarize the preclinical, pharmacokinetic and clinical data for
panobinostat in MM